Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 26 2023 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the Canaccord Genuity 43rd Annual Growth Conference, which takes
place August 7-10, 2023, at the InterContinental Boston Hotel in
Boston, MA. John Aballi, Exagen’s President and Chief Executive
Officer and Kamal Adawi, Exagen’s Chief Financial Officer, will
present on Wednesday, August 9th, at 3:00 PM ET. Interested parties
may access the webcast of the presentation using a link on Exagen’s
website at https://investors.exagen.com/events.
About Exagen Inc.
Exagen is a leading provider of autoimmune diagnostic,
prognostic and monitoring testing solutions. Exagen is a
patient focused, discovery driven organization built on the success
of AVISE® testing and is investing in its product pipeline to
support patients throughout their autoimmune diagnosis and
treatment journeys. The goal at Exagen is to assist patients,
physicians and payors by enabling precision
medicine. Exagen is located in San Diego County.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen's
current beliefs and expectations. The inclusion of forward-looking
statements should not be regarded as a representation by Exagen
that any of its plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Exagen’s business, including, without
limitation: impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests causing an
increase in cost per test, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products among rheumatologists, patients,
third-party payors and others in the medical community; Exagen’s
ability to successfully execute on its business strategies; third
party payors not providing coverage and adequate reimbursement for
Exagen’s testing products, including Exagen’s ability to collect on
funds due; Exagen’s ability to obtain and maintain intellectual
property protection for its testing products; regulatory
developments affecting Exagen’s business; and other risks described
in Exagen’s prior press releases and Exagen’s filings with the
Securities and Exchange Commission (“SEC”), including under the
heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for
the year ended December 31, 2022 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc. Ryan
Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024